sulfasalazine has been researched along with Glioblastoma in 8 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide (TMZ) is an alkylating agent used to treat glioblastoma." | 7.83 | Sulfasalazine intensifies temozolomide cytotoxicity in human glioblastoma cells. ( Castilho, RF; De Melo, DR; Facchini, G; Ignarro, RS; Lopes-Cendes, I; Rogerio, F; Vieira, AS, 2016) |
| "Glioblastoma multiforme is the most aggressive malignant primary brain tumor in adults." | 5.43 | Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance. ( Aboody, KS; Cassady, K; Cherryholmes, GA; Marinov, GK; Polewski, MD; Reveron-Thornton, RF, 2016) |
| "Glioblastomas, the most common primary brain cancers, respond poorly to current treatment modalities and carry a dismal prognosis." | 5.32 | In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. ( Bentires-Alj, M; Black, PM; Bonif, M; Bours, V; Deprez, M; Erkmen, K; Haddada, H; Jolois, O; Khac, MT; Merville, MP; Robe, PA; Rogister, B, 2004) |
| "Temozolomide (TMZ) is an alkylating agent used to treat glioblastoma." | 3.83 | Sulfasalazine intensifies temozolomide cytotoxicity in human glioblastoma cells. ( Castilho, RF; De Melo, DR; Facchini, G; Ignarro, RS; Lopes-Cendes, I; Rogerio, F; Vieira, AS, 2016) |
| "Glioblastoma multiforme is the most aggressive malignant primary brain tumor in adults." | 1.43 | Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance. ( Aboody, KS; Cassady, K; Cherryholmes, GA; Marinov, GK; Polewski, MD; Reveron-Thornton, RF, 2016) |
| "Glioblastomas (GBMs) are aggressive brain tumors that always recur after radiotherapy." | 1.42 | Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion. ( Dodoo, E; Enger, PØ; Førde, HE; Heggdal, JI; Leiss, L; Netland, IA; Pedersen, PH; Selheim, F; Skeie, BS; Sleire, L; Wang, J, 2015) |
| "Glioblastomas, the most common primary brain cancers, respond poorly to current treatment modalities and carry a dismal prognosis." | 1.32 | In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. ( Bentires-Alj, M; Black, PM; Bonif, M; Bours, V; Deprez, M; Erkmen, K; Haddada, H; Jolois, O; Khac, MT; Merville, MP; Robe, PA; Rogister, B, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia, CG | 1 |
| Kahn, SA | 1 |
| Geraldo, LHM | 1 |
| Romano, I | 1 |
| Domith, I | 1 |
| Silva, DCLE | 1 |
| Dos Santos Assunção, F | 1 |
| Ferreira, MJ | 1 |
| Portugal, CC | 1 |
| de Souza, JM | 1 |
| Romão, LF | 1 |
| Netto, ADP | 1 |
| Lima, FRS | 1 |
| Cossenza, M | 1 |
| Chen, L | 1 |
| Li, X | 1 |
| Liu, L | 1 |
| Yu, B | 1 |
| Xue, Y | 1 |
| Liu, Y | 1 |
| Sleire, L | 1 |
| Skeie, BS | 1 |
| Netland, IA | 1 |
| Førde, HE | 1 |
| Dodoo, E | 1 |
| Selheim, F | 1 |
| Leiss, L | 1 |
| Heggdal, JI | 1 |
| Pedersen, PH | 1 |
| Wang, J | 1 |
| Enger, PØ | 1 |
| Ignarro, RS | 1 |
| Facchini, G | 1 |
| Vieira, AS | 1 |
| De Melo, DR | 1 |
| Lopes-Cendes, I | 1 |
| Castilho, RF | 1 |
| Rogerio, F | 1 |
| Polewski, MD | 1 |
| Reveron-Thornton, RF | 1 |
| Cherryholmes, GA | 1 |
| Marinov, GK | 1 |
| Cassady, K | 1 |
| Aboody, KS | 1 |
| Takeuchi, S | 1 |
| Nawashiro, H | 1 |
| Robe, PA | 1 |
| Bentires-Alj, M | 1 |
| Bonif, M | 1 |
| Rogister, B | 1 |
| Deprez, M | 1 |
| Haddada, H | 1 |
| Khac, MT | 1 |
| Jolois, O | 1 |
| Erkmen, K | 1 |
| Merville, MP | 1 |
| Black, PM | 1 |
| Bours, V | 1 |
| Lyons, SA | 1 |
| Chung, WJ | 1 |
| Weaver, AK | 1 |
| Ogunrinu, T | 1 |
| Sontheimer, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial Combining Sulfasalazine and Gamma Knife Radiosurgery for Recurrent Glioblastoma[NCT04205357] | Phase 1 | 24 participants (Actual) | Interventional | 2020-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 other studies available for sulfasalazine and Glioblastoma
| Article | Year |
|---|---|
Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.
Topics: Amino Acid Transport System y+; Animals; Ascorbic Acid; Brain Neoplasms; Cell Death; Cell Line, Tumo | 2018 |
Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion.
Topics: Amino Acid Transport System y+; Animals; Brain Neoplasms; Cell Line, Tumor; Cystine; DNA; Drug Repos | 2015 |
Sulfasalazine intensifies temozolomide cytotoxicity in human glioblastoma cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytotoxins; Dacarbazine; Drug Screening Assays, | 2016 |
Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.
Topics: Amino Acid Transport System y+; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2016 |
NFKBIA deletion in glioblastomas.
Topics: ErbB Receptors; Gene Deletion; Glioblastoma; Humans; I-kappa B Proteins; NF-kappa B; NF-KappaB Inhib | 2011 |
In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; G | 2004 |
Autocrine glutamate signaling promotes glioma cell invasion.
Topics: Amino Acid Transport System y+; Animals; Brain Neoplasms; Calcium; Cell Line, Tumor; Cell Movement; | 2007 |